UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
NEWS
Sequence variants that affect IgG subclass levels
Scientists at deCODE genetics, a subsidiary of Amgen, and collaborators have published a study in Nature Communications reporting sequence variants that affect subclass levels of Immunoglobulin G (IgG) in blood.
Three common variants increase the risk of Wolff-Parkinson-White syndrome
A new study was published today in Jama Cardiology, by scientists at deCODE genetics/Amgen and collaborators, on the genetics of accessory conduction pathways in the heart (Wolff-Parkinson-White syndrome). It reveals that accessory pathways can cause rhythm disturbances, characterized by an overly fast heartbeat, which can be life-threatening.
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.